ADEMETIONINE THERAPY IN CHRONIC LIVER DISEASES
https://doi.org/10.21518/2079-701X-2016-9-124-129
Abstract
Drug- and alcohol-induced liver injuries are the most common reason for the chronic liver diseases. For the past 10years, in Russia ademetionine products have been used in treatment of such diseases to provide detoxification and antioxidant effects, normalize the permeability of the cell membranes, accelerate regeneration of liver cells and slow down the development of fibrosis. The numerous studies showed that the use of ademetionine improves a protein synthesis in the liver, reduces the severity of lipid exchange violations, contributes to positive dynamics of serum biochemical parameters (ALP, GGTP, ALT, AST, bilirubin) and regresses clinical manifestations of the astenovegetative and dyspeptic syndromes, while tolerability of ademetionine is favorable [15, 17, 18].
About the Authors
N. V. TOPCHIY
Peoples’ Friendship University of Russia; Association of General Practitioners (Family Practitioners) of the Russian Federation; Sechenov First Moscow State Medical University
Russian Federation
Cand. Med. Sc.
Russian Federation
Cand. Med. Sc.
A. S. TOPORKOV
Association of General Practitioners (Family Practitioners) of the Russian Federation; Sechenov First Moscow State Medical University; City Outpatient Clinic No 68 of the Department of Public Health, Moscow
Russian Federation
Cand. Med. Sc.
Russian Federation
Cand. Med. Sc.
N. N. KUZENKOVA
Peoples’ Friendship University of Russia; City Outpatient Clinic No 68 of the Department of Public Health, Moscow
Russian Federation
Russian Federation
References
1. Абдурахманов Д.Т., Моисеев С.В. Лекарственные поражения печени. Фарматека. 2011, 17: 67-73. / Abdurakhmanov D.T., Moiseyev S.V. Drug-induced liver injuries. Pharmateka. 2011, 17: 67-73.
2. Бабанина Н.В. Опыт применения адеметионина у онкологических пациентов, получающих противоопухолевое лечение. Лечащий врач, 2013, 2: 62-64. / Babanina N.V. Experience in application of ademetionine in cancer patients receiving anticancer therapy. Attending Practitioner, 2013, 2: 62-64.
3. Буеверов А.О. Адеметионин: биологические функции и терапевтические эффекты. Клинические перспективы гастроэнтерологии, гепатологии, 2001, 3: 1-4. / Bueverov S.A. Ademetionin: biological functions and therapeutic effects. Clinical Prospects of Gastroenterology, Hepatology, 2001, 3: 1-4.
4. Буторова Л.И. Калинин А.В., Логинов А.Ф. Лекарственные поражения печени. Учебно-методическое пособие. Институт усовершенствования врачей. ФГУ «НМХЦ им. Н.И. Пирогова». М. 2010. 64 с. / Butorova L.I., Kalinin A.V., Loginov A.F. Drug-induced liver injuries. Study guide. Physicians’ Continuing Education Institute. The Pirogov National Medical Surgical Center. 2010. P. 64.
5. Звенигородская Л.А., Лазебник Л.Б., Черкашова Е.А., Ефремов Л.И. Статиновый гепатит. Трудный пациент, 2009, 7(4-5): 44-49. / Zvenigorodskaya L.A., Lazebnik L.B., Cherkashova E.A., Efremov L.I. Statin-induced hepatitis. Difficult Patient, 2009 7, (4-5): 44-49.
6. Ивашкин В.Т., Жаркова М.С., Маевская М.В., Лапшин А.В. Случай тяжелого лекарственного гепатита, индуцированного длительным приемом кордарона. Российские медицинские вести, 2009, ХIV(2): 78-83. / Ivashkin V.T., Zharkova M.S., Maevskaya M.V., Lapshin A.V. Case of severe drug-induced hepatitis induced by prolonged cordarone therapy. Russian Medical News, 2009, XIV (2): 78-83.
7. Игнатова Т.М. Лекарственные поражения печени. Гепатологический форум, 2008, 2: 2-8. / Ignatova T.M. Drug-induced liver injuries. Hepatology Forum, 2008, 2: 2-8.
8. Ильченко Л.Ю. Отечественный препарат адеметионина: десять лет применения при алкогольной болезни печени. Doктор. Ру. Гастроэнтерология, 2015, 12(113): 14-15. / Ilchenko L.U. Domestic drug Ademetionine: ten-year use in alcoholic liver disease. Doсtor. Ru. Gastroenterology, 2015, 12 (113): 14-15.
9. Казюлин А.Н., Вельшер Л.З., Данилевская Н.Н., Маевская Е.А. Лекарственная гепатоток сичность при проведении противоопухолевой химиотерапии онкологических заболеваний и возможность ее коррекции. Фарматека, 2012, 8: 1-7. / Kazyulin A.N., Velsher L.Z., Danilevskaya N.N., Maevskaya E.A. Drug hepatotoxicity in anticancer chemotherapy of oncological diseases and its correction. Pharmateka, 2012, 8: 1-7.
10. Камалов Ю.Р. Руководство по абдоминальной ультразвуковой диагностике при заболеваниях печени. М., 2008, 174 с. / Kamalov Yu.R. Guide on abdominal ultrasound in liver diseases. M., 2008, 174 p.
11. Корнеева О.Н., Драпкина О.М. Как избежать гепатотоксичности при назначении статинов у пациентов с ожирением и сопутствующей пато логией печени? Кардиоваскулярная терапия и профилактика, 2012, 11(6): 81-84. / Korneeva O.N., Drapkina O.M. How to avoid hepatotoxicity in statin therapy in patients with obesity and related liver pathologies? Cardiovascular therapy and prevention, 2012, 11 (6): 81-84.
12. Маев И.В., Полунина Т.Е. Лекарства и печень. Фарматека, 2013, 2: 1-14. / Maev I.V., Polunina T.E. Drugs and the liver. Pharmateka, 2013, 2: 1-14.
13. Мехтиев С.Н., Мехтиева О.А., Зиновьева Е.Н. Неалкогольная жировая болезнь печени в вопросах и ответах. Учебное пособие. СПб., 2011. 53 с. / Mekhtiev S.N., Mekhtiev O.A., Zinovieva E.N. Non-alcohol induced fatty liver disease: questions and answers. Tutorial. St. Petersburg. 2011.53 p.
14. Минушкин О.Н. Гептрал в лечении хронических заболеваний печени. Российский гастро-энтерологический журнал, 2001, 3. / Minushkin O.N. Heptral in the treatment of chronic liver diseases. Russian Gastroenterology Journal 2001, 3.
15. Мордасова В.И. Гептор в лечении алкогольной болезни печени. РМЖ, 2010, 18(13): 824-829. / Mordasova V.I. Heptor in treatment of alcoholic liver disease. RMJ, 2010, 18 (13): 824-829.
16. Рейзис А.Р., Борзакова С.Н., Аксенова В.А. Гепатит, индуцированный туберкулостатическими препаратами. Российские медицинские вести, 2011, ХVI(1): 1-7. / Reizis A.R., Borzakova S.N., Aksenova V.F. Hepatitis induced by tuberculosis drugs. Russian medical news, 2011, XVI (1): 1-7
17. Снеговой А.В., Манзюк Л.В. Эффективность Гептрала в лечении печеночной недостаточности, обусловленной цитотоксической химиотерапией. Фарматека, 2010, 6: 1-5. / Snegovoi A.V., Manzyuk L.V. Efficacy of Heptral in the treatment of liver failure caused by cytotoxic chemotherapy. Pharmateka, 2010, 6: 1-5.
18. Ткаченко Е.И., Успенский Ю.П., Скворцова Т.Э. Клинические возможности препарата адеметионина «Гептор» с лечении больных с алкогольной болезнью печени. Экспериментальная клиническая гастроэнтерология, 2008, 2: 106- 112. / Tkachenko E.I., Uspensky Yu.P., Skvortsova T.E. Clinical features of the ademetionine drug Heptor in the treatment of patients with alcoholic liver disease. Experimental & Clinical Gastroenterology, 2008, 2: 106-112.
19. Топорков А.С. Применение эссенциальных фосфолипидов в терапии алкогольной болезни печени. РМЖ, 2003, 14: 836-838. / Toporkov A.S. Application of essential phospholipids in the treatment of alcoholic liver disease. RMJ, 2003, 14: 836-838.
20. Хомерики С.Г. Патогенетически механизмы и морфологические проявления лекарственных поражений печени. Эспериментальная и клиническая гастроэнтерология, 2011, 6: 11-21. / Khomeriki S.G. Pathogenetical mechanisms and morphological manifestations of drug-induced liver diseases. Experimental & Clinical Gastroenterology, 2011, 6: 11-21.
21. Хомерики С.Г., Хомерики Н.М. Лекарственные поражения печени. Учебное пособие для врачей. М. 2012. 40 с. / Khomeriki S.G., Khomeriki N.M. Drug-induced liver injuries. Tutorial for the physicians. M. 2012. 40 p.
22. Шикалова И.А., Шилов В.В., Васильев С.А., Батоцыренов Б.В., Лоладзе А.Т. Фармакологическая коррекция токсических поражений печени у больных с тяжелыми формами острых отравлений этанолом. Экспериментальная и клиническая фармакология, 2012, 4(75): 30-33. / Shikalova I.A., Shylov V.V., Vasiliev S.A., Batocyrenov B.V., Loladze A.T. Pharmacological correction of toxic liver diseases in patients with severe forms of acute ethanol poisoning. Experimental & Clinical Pharmacology, 2012, 4 (75): 30- 33.
23. Шульпекова Ю.О. Лекарственные поражения печени. Consilium medicum, 2006, 8(7): 5-6. / Shulpekova U.O. Drug-induced liver diseases. Consilium medicum, 2006, 8 (7): 5-6.
24. Яковенко Э.П. и соавт. Лекарственно-индуцирован ный поражения печени. Диагностика и лечение. Лечащий врач, 2011, 2: 2-7. / Yakovenko E.P. et al. Drug-induced liver injury. Diagnosis and treatment. Attending Physician, 2011, 2: 2-7.
25. Andrade RJ, Lucena MI, Fernandes MC et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year periode. Gastroenterol., 2005, 129(2): 512-521.
26. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus mrrting. J. Hepatol., 1990, 11: 272-276.
27. Di Perri T, Sacco T, Festi D. Ademethionin in the treatment of chronic liver disease: A multicenter study. Gastroenttrol., 1999, 12(4): 62-68.
28. Field KM, Dow C, Michael M. Part 1: Liver function in oncology: biochemistry and beyond. Lancet Oncol., 2008, 9(11): 1092-1101.
29. Floyd I, Mirza I, Sacts B et al. Hepatotoxicity of chemjtherapy. Semin. Oncol., 2006, 33(1): 50-67.
30. Forelli G. S-adenosylmethionine in treatment of intrahepatic cholestasis of chronic liver disease: A field trial. Curr. Ther. res., 1999, 60(6): 335-348.
31. Frezza M, Terpin M. Thr use of S-adenosyl-Lmethionine in the treatment of cholestatic disorders: A metaanalisys of clinical trials. Drug invest., 1992, 4(4): 101-108.
32. Holt MP, Ju C. Mechanisms of drug-induced liver injury. A.A.P.S., 2006, 8: E48-E54.
33. Lee WM. Drug-induced hepatptoxicity. N. Eng. J. Mtd., 2003, 342: 474-485.
34. Mato JM, Camara J, Fernandez de Paz J et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, doubleblind, multicenter clinical trial. Hepatology, 1999, 30: 1081-1089.
35. Mato JM, Shelly C. Lu Role of S-Adenosyl-LMethionine in liver health and injury. Hepatology, 2007, 45: 1306-1312.
36. Nei S, Signorelli S, Sterna D et al. The role of adenomethionine (S-adenosylmethionine) in the prevention of cyclosporine-induced cholestasis. Clin. Drug Invest., 2002, 22(3): 191-195.
37. Pauli-Magnus C, Majer PJ. Hepatobiliary transporters and drug-induced cholestasis. Hepatology, 2006, 44: 778-787.
38. Santini D, Vincenzi B, Massacesi C et al. S-adenosylmethionine (AdoMet) supplementation for treatment of chemotherapy-induced liver injury. Anticancer Res., 2003, 23: 5173-5180.
39. Sgro C, Clinard K,Ouazir K et al. Incidence of drug-induced hepatic injuries: a French population- based study. Hepatology, 2002, 36(2): 451-455.
40. Vincenzi B, Santini D, Frezza AM et al. The role of S-adenosylmethionine in preventing FOLFOX-induced liver toxicity: a retrospective analysis in patiens affected by resected colorectal cancer treated with adjuvant FOLFOX regimen. Expert. Opin Drag Saf., 2011, 10(3): 345-349.
41. Vincenzi B, Daniele S, Frezza AM. The role of S-adenosylmethionine in preventing oxaliplatin- induced liver toxicity: a retrospective analysis in metastatic colorectal cancer patients treated with bevacizumab plus oxaliplatin- based regimen. Suup. care cancer, 2012,
42. (1): 135-139.
Review
For citations:
TOPCHIY NV, TOPORKOV AS, KUZENKOVA NN. ADEMETIONINE THERAPY IN CHRONIC LIVER DISEASES. Meditsinskiy sovet = Medical Council. 2016;(9):124-129. (In Russ.) https://doi.org/10.21518/2079-701X-2016-9-124-129
Views:
1001
Email this article 